Litcius/Paper detail

Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial

Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Benjamin N. Greener, Ye Zhang, Judd L. Walson

2023The Lancet Infectious Diseases119 citationsDOIOpen Access PDF

Topics & Concepts

ImmunogenicityCoronavirus disease 2019 (COVID-19)MedicineBooster doseBooster (rocketry)Virology2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyAntibodyInternal medicineInfectious disease (medical specialty)TiterOutbreakVirusDiseaseAstronomyPhysicsSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesSARS-CoV-2 detection and testing
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial | Litcius